Dataset opportunity
Southmedic — 监管记录数据集机会
Southmedic 持有的中等规模监管记录数据集,可用于监管 RAG 和合规性 Copilots。
Score
65.8
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
收购
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球监管事务人工智能市场 = 2024 年为 13.1 亿美元,复合年增长率为 18.60%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
监管记录数据集
Modality
文本
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高(专有)
Accessibility
受限
Legal
公司所有 — 许可权待明确
Buyer persona
RegTech 和合规性 AI 供应商
Southmedic 持有一个文本模态的监管记录数据集,其中包含其质量管理系统中的专有工业数据和业务记录。这些数据包括加拿大卫生部和 FDA 提交的证据,对于训练监管 RAG 系统以自动化和提高合规性文档和查询的准确性具有极高的价值。
该数据的价值在全球监管事务人工智能市场中得到体现,该市场在 2024 年的估值为13.1 亿美元,预计将以 18.60% 的复合年增长率增长。尽管由于专有制造知识产权和医疗器械监管限制而存在访问复杂性,但该数据集的稀有性和直接适用性使其成为寻求在此快速增长的市场中获得竞争优势的 AI 买家的高价值资产。⚠ 尽职调查(有价值的数据,可协商的访问权限):医疗器械监管限制(加拿大卫生部/FDA);专有制造知识产权和商业秘密;数据可能存储在孤立的质量管理系统(QMS)中 · 公司:独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Southmedic 持有一个专有的、稀有度高的数据集,详细说明了其医疗器械的监管、质量和临床结果。对于 RegTech 和合规性 AI 供应商而言,这是构建和训练下一代监管 RAG 系统的关键资产。在全球监管事务人工智能市场预计于 2024 年达到 13.1 亿美元的背景下,这个独特的数据集——涵盖了制造合规性和分销到80 多个国家——通过提供实际的性能数据,而这些数据通常无法获得,从而提供了独特的竞争优势。
See dimension details ↓- Dataset Specificity78
主导的“监管”,医疗保健行业,2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于监管 RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
AI 买家需求旺盛,这得益于在全球监管事务人工智能市场(以 18.60% 的复合年增长率增长)中对效率和自动化的需求。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility28
受限/未知
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility30
中等难度,独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型,3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License70
所有权=公司所有,许可=权利不明确
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据需求信号(2 种类型)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus70
盈余=中等 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ 良好目标 — Southmedic 是一个不错的目标,因为它是一家私营医疗器械制造商和分销商,其核心业务是销售实体产品,而不是数据,并且为 80 多个国家/地区所需的监管合规性可能产生了宝贵、休眠的数据集。问题:员工人数因来源而异,公司自己的网站称“600 多人”,而其他来源估计在 381-500 人之间,但仍符合范围;“监管记录数据集”是基于其运营概况推断的机会,而不是明确提及的资产;价值来自数据
- Deep Qualification90
✓ 通过 — Southmedic 是一家医疗器械制造商和分销商。其核心业务需要为加拿大卫生部和 FDA 等机构创建和维护广泛的监管记录,使其成为一个主要的数据持有者,拥有高价值的专有数据集。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Industrial data
这些证据表明存在广泛的ISO 合规生产和质量测试数据集,这是任何验证制造声明以用于监管提交的 AI 系统的基础。
Regulatory records
这些证据证实持有者拥有关于其设备性能和临床结果的专有文本数据,这是为旨在自动化合规性和报告的监管 RAG 系统设计的理想燃料。
business_records
这些证据证实了全球运营足迹,分销记录遍布80 多个国家,这强烈表明该数据集包含与广泛的国际监管框架相关的文件。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Southmedic Regulatory Records — a Moderate regulatory records dataset (Text modality) in the healthcare domain. Primary AI use-case: Regulatory RAG. Market signal: Global AI in regulatory affairs market = $1.31B in 2024, CAGR 18.60% (source: Grand View Research). Investment score 65.8/100 (confidence 0.49). Recommended action: Acquire.
From the marketplace
Explore live data opportunities
Radiantnuclear — 监管记录数据集机会
View opportunity →工业Selva Electronique — 法规记录数据集机会
View opportunity →移动出行Willsonintl — 法规记录数据集机会
View opportunity →